相关实验视频
Updated: Jul 14, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
COX-1,COX-2和COX-3以及慢性炎症疾病的未来治疗方法
D A Willoughby1, A R Moore, P R Colville-Nash
1Department of Experimental Pathology, William Harvey Research Institute, St Bartholomew's and Royal London Hospital Schools of Medicine & Dentistry, UK. d.a.willoughby@mds.qmw.ac.uk
新的研究表明,在炎症解消期间抑制循环氧酶2 (COX-2) 可以延长炎症反应. 这挑战了选择性COX-2抑制剂的治疗潜力,并提出了一个新的点,COX-3.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 非类固醇抗炎药物 (NSAIDs) 传统上抑制循环氧酶1 (COX-1) 和循环氧酶2 (COX-2).
- 选择性COX-2抑制剂是为了减少与COX-1抑制相关的胃肠道副作用而开发的.
- 已知COX-2在炎症部位表达.
研究的目的:
- 研究COX-2在炎症解消阶段的作用.
- 评估COX-2抑制对炎症过程的影响.
- 探索一种新型环氧酶异形COX-3的潜在存在和治疗影响.
主要方法:
- 利用特定的抗体来识别和跟踪COX-2表达.
- 服用COX-2抑制剂,观察它们对炎症分辨率的影响.
- 分析了与COX-2活性相关的前列腺素的合成.
主要成果:
- 发现COX-2在炎症解消期间被诱导.
- 抑制COX-2导致炎症的持续.
- 这种抑制阻止了关键的抗炎性前列腺素的合成.
结论:
- 与之前的假设相反,COX-2在解决炎症方面发挥着至关重要的作用.
- 选择性COX-2抑制可能没有益处,可能会加剧炎症.
- 提出了第三种循环氧原酶异型,COX-3,它代表了潜在的炎症条件的新治疗标.
更多相关视频
05:36Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
Published on: October 4, 2024
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Rheumatic Heart Disease III: Medical Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Acute Inflammation III: Local and Systemic Effects